Literature DB >> 20555089

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

F Roila1, J Herrstedt, M Aapro, R J Gralla, L H Einhorn, E Ballatori, E Bria, R A Clark-Snow, B T Espersen, P Feyer, S M Grunberg, P J Hesketh, K Jordan, M G Kris, E Maranzano, A Molassiotis, G Morrow, I Olver, B L Rapoport, C Rittenberg, M Saito, M Tonato, D Warr.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20555089     DOI： 10.1093/annonc/mdq194

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  255 in total

1.  Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews.

Authors:  Julie L Eiseman; Jan H Beumer; Lora H Rigatti; Sandra Strychor; Kelly Meyers; Samuel Dienel; Charles C Horn
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-15       Impact factor: 3.333

Review 2.  Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles.

Authors:  Juan Bayo; Paula J Fonseca; Susana Hernando; S Servitja; A Calvo; S Falagan; Estefanía García; Iria González; María José de Miguel; Quionia Pérez; Ana Milena; Antonio Ruiz; Agustí Barnadas
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

3.  Netupitant/Palonosetron.

Authors:  Dennis J Cada; James Leonard; Danial E Baker
Journal:  Hosp Pharm       Date:  2015-04-08

4.  Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2015-03

Review 5.  Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different?

Authors:  Jill M Kolesar; Jens Eickhoff; Lee C Vermeulen
Journal:  Am J Health Syst Pharm       Date:  2014-03-15       Impact factor: 2.637

Review 6.  Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.

Authors:  Karin Jordan; Luisa Blättermann; Axel Hinke; Carsten Müller-Tidow; Franziska Jahn
Journal:  Support Care Cancer       Date:  2017-08-31       Impact factor: 3.603

7.  Palonosetron exhibits higher total control rate compared to first-generation serotonin antagonists and improves appetite in delayed-phase chemotherapy-induced nausea and vomiting.

Authors:  Hiroki Ueda; Chigusa Shimono; Tomoyasu Nishimura; Megumi Shimamoto; Hiroki Yamaue
Journal:  Mol Clin Oncol       Date:  2014-02-20

Review 8.  Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.

Authors:  Christopher M Hocking; Ganessan Kichenadasse
Journal:  Support Care Cancer       Date:  2014-02-13       Impact factor: 3.603

9.  Impact of a complementary/integrative medicine program on the need for supportive cancer care-related medications.

Authors:  Ilanit Shalom-Sharabi; Noah Samuels; Efraim Lev; Ofer Lavie; Lital Keinan-Boker; Elad Schiff; Eran Ben-Arye
Journal:  Support Care Cancer       Date:  2017-04-22       Impact factor: 3.603

Review 10.  Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.

Authors:  Hyun Jin Song; Hyun-Ju Seo; Heejeong Son
Journal:  Eur J Clin Pharmacol       Date:  2016-08-15       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.